Skip to main content

Advertisement

SpringerLink
Log in

Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma

  • PHASE II STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Lenalidomide (CC-5013) is a structural derivative of thalidomide, with antiangiogenic and immunomodulatory effects. Fourteen patients with metastatic renal cell carcinoma (RCC) were enrolled on a phase 2 trial of lenalidomide administered orally at 25 mg daily for 21 days followed by a rest period of 7 days. The best response was stable disease in eight patients (57%) of the 14 evaluable patients. Toxicities included fatigue, hyperglycemia, dyspnea, and myelosuppression with decreased hemoglobin, lymphopenia, and neutropenia. Lenalidomide is tolerable, but no objective responses were observed in this clinical trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335(12):865–875

    Article  PubMed  CAS  Google Scholar 

  2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124

    Article  PubMed  CAS  Google Scholar 

  3. Hudes GMC, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, O’Toole T, Park Y, Moore L (2006) A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR+IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). American Society of Clinical Oncology

  4. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427–434

    Article  PubMed  CAS  Google Scholar 

  5. Knight R (2005) IMiDs: a novel class of immunomodulators. Semin Oncol 32(4 Suppl 5):S24–S30

    Article  PubMed  CAS  Google Scholar 

  6. Kumar S, Rajkumar SV (2006) Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 42(11):1612–1622

    Article  PubMed  CAS  Google Scholar 

  7. Bartlett JB, Tozer A, Stirling D, Zeldis JB (2005) Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer 93(6):613–619

    Article  PubMed  CAS  Google Scholar 

  8. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV (2006) Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108(2):618–621

    Article  PubMed  CAS  Google Scholar 

  9. Choueiri TK, Dreicer R, Rini BI, Elson P, Garcia JA, Thakkar SG, Baz RC, Mekhail TM, Jinks HA, Bukowski RM (2006) Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 107(11):2609–2616

    Article  PubMed  CAS  Google Scholar 

  10. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1–10

    Article  PubMed  CAS  Google Scholar 

  11. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(1):289–296

    Article  PubMed  CAS  Google Scholar 

  12. D’Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91(9):4082–4085

    Article  PubMed  CAS  Google Scholar 

  13. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME (2000) Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82(4):812–817

    Article  PubMed  CAS  Google Scholar 

  14. Minor DR, Monroe D, Damico LA, Meng G, Suryadevara U, Elias L (2002) A phase II study of thalidomide in advanced metastatic renal cell carcinoma. Invest New Drugs 20(4):389–393

    Article  PubMed  CAS  Google Scholar 

  15. Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R (2002) A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 95(4):758–765

    Article  PubMed  CAS  Google Scholar 

  16. Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, Leborgne S, Garofano A, Leboulaire C, Dupouy N, Laplanche A (2002) Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 13(7):1029–1035

    Article  PubMed  CAS  Google Scholar 

  17. Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J, Mazumdar M (2002) Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 20(1):302–306

    Article  PubMed  CAS  Google Scholar 

  18. Gordon MS et al (2004) Low dose interferon-α2b (IFN) + thalidomide (T) in patients (pts) with previously untreated renal cell cancer (RCC). Improvement in progression-free survival (PFS) but not quality of life (QoL) or overall survival (OS). A phase III study of the Eastern Cooperative Oncology Group (E2898). American Society of Clinical Oncology

  19. Marsh L et al (2006) Phase II study of lenalidomide in patients (pts) with metastatic renal cell cancer (MRCC. American Society of Clinical Oncology

Download references

Acknowledgements

This trial was supported by Celgene, Inc (Summit, New Jersey).

Author information

Authors and Affiliations

  1. Genitourinary Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA

    Premal H. Patel, G. Varuni Kondagunta, John DeLuca & Robert J. Motzer

  2. Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA

    Lawrence Schwartz

  3. Department of Biostatistics, Epidemiology and Statistics, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA

    Nicole Ishill & Jennifer Bacik

  4. Department of Surgery, Urologic Service, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA

    Paul Russo

  5. Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10021, USA

    Robert J. Motzer

Authors
  1. Premal H. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Varuni Kondagunta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lawrence Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nicole Ishill
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jennifer Bacik
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John DeLuca
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paul Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Robert J. Motzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert J. Motzer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patel, P.H., Kondagunta, G.V., Schwartz, L. et al. Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Invest New Drugs 26, 273–276 (2008). https://doi.org/10.1007/s10637-007-9107-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-007-9107-y

Keywords

Search

Navigation